FLT3 and acute myeloid leukemia: In this study, we docked the MD output (average structure at 200 ns) of the native and mutant FLT3 proteins with 10 AML inhibitors (Crenolanib, FF-10101, Gilteritinib, KW-2449, PLX3397, Ponatinib, Quizartinib, Sorafenib, Sunitinib, and Tandutinib) to observe the interaction behavior of individual D835 mutations of FLT3 proteins with inhibitors.